Phylo partners with Bayer to deploy Biomni Lab AI agents in drug research

Phylo announced a partnership with Bayer to give its scientists full access to Biomni Lab, an agentic AI platform for literature and omics evidence workflows in drug discovery. Each result preserves sources, methods and code so researchers can inspect and reproduce the analysis.

• Bayer gains full access to the Biomni Lab agentic AI platform
• Platform combines scientific literature, biomedical data and analytical methods
• Every result keeps sources, methods and code for verification
• Biomni Lab builds on the open-source Biomni project from Stanford